Back to today’s briefing

Story perspectives

Sarepta Cuts 500 Jobs Amid Elevidys Safety Concerns

7/18/2025

28 4

Summary

Sarepta Cuts Jobs

Sarepta Therapeutics is making drastic changes, cutting 500 jobs—36% of its workforce—to save $400 million each year. This decision comes on the heels of safety worries surrounding its gene therapy, Elevidys, which has been linked to two tragic patient deaths. The FDA is set to impose a black box warning on Elevidys, despite its impressive $282 million revenue in Q2.

Summary

Sarepta Launches Trials

Sarepta Therapeutics has launched a Phase 1/2 trial for SRP-9001, aiming to combat Duchenne muscular dystrophy, igniting a remarkable 237.66% surge in trading volume. Meanwhile, promising interim results from SRP-5051 for limb-girdle muscular dystrophy have fueled investor optimism. Yet, shadows loom over Elevidys, grappling with a black box warning and legal challenges after tragic patient deaths.

1 of 2

Sarepta Cuts Jobs

Sarepta Therapeutics is making drastic changes, cutting 500 jobs—36% of its workforce—to save $400 million each year. This decision comes on the heels of safety worries surrounding its gene therapy, Elevidys, which has been linked to two tragic patient deaths. The FDA is set to impose a black box warning on Elevidys, despite its impressive $282 million revenue in Q2.

1 / 2